RECTAL cancerMetastatic colon cancer remains an incurable disease, and it is difficult for existing treatments to achieve the desired clinical outcome, especially for colon cancer patients who have received first-line treatment. Although immune checkpoint inhibitors (ICIs) have...
The phosphoinositide 3-kinase (PI3K)–Akt axis is one of the most frequently activated pathways and is demonstrated as a therapeutic target in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated colorectal cancer (CRC). Targeting the PI3K–Akt pathway has been a challenging undertaking through...
FULL PAPER British Journal of Cancer (2015) 112, 1874–1881 | doi: 10.1038/bjc.2015.144 Keywords: pimasertib; MEK inhibitor; FOLFIRI; KRAS-mutated metastatic colorectal cancer; combination therapy second-line treatment Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-...
In the current study, cancer cell growth inhibitory properties of TAK1 inhibition were determined in KRAS mutant colon cancer cells. The results demonstrate that treatment with the TAK1 inhibitor 5Z-7-oxozeaenol decreases cancer cell viability, cell growth rate, and clonogenic cell survival. These...
Transforming growth factor β-activated kinase 1 (TAK1) is critical for survival of many KRAS mutated colorectal cancer cells, and TAK1 inhibition with 5Z-7-oxozeaenol has been associated with oxidative stress leading to tumor cell killing. When SW 620 and HCT 116 human colon cancer cells wer...
An overview of new data presented at the American Society of Clinical Oncology 2021 annual meeting for KRAS G12C-mutated non–small cell lung cancer (NSCLC). EP: 1.NSCLC: ADAURA Trial Results EP: 2.ADAURA Trial Results and NSCLC Treatment Decisions EP: 3.First Generation TKIs in NSCLC EP...
This data, taken together, explain why vertical suppression of EGFR/MAPK pathway has only a transient effect in KRAS-driven colorectal cancers and stimulate new research on the best treatment approach for this aggressive cancer type, encouraging further evaluation of novel combination strategies ...
CONCLUSIONS: This is the first head to head comparison of cetuximab versus bevacizumab in first-line treatment of mCRC. In the present evaluation of patients with KRAS-mutated tumours, neither strategy demonstrated a clearly superior outcome. 展开 关键词: bevacizumab cetuximab colon cancer first-line...
cancer cells, we investigated whether this correlates with an increased pool of labile ferrous iron. In HCT116 cells, ferrous ion (Fe2+) levels were significantly increased upon STS and vitamin C co-treatment compared with all other conditions (Fig.3a), suggesting a potential role of iron in ...
(1CM) and epigenetic regulation are known to be dysregulated by aberrant KRAS activity, we still lack evidence that co-treatment with drugs that regulate these factors might ameliorate response rates and patient prognosis. In this study, we show a direct dependency of Methylenetetrahydrofolate ...